In a model of Hepa 1-6 cell-derived liver tumors, developed in otherwise unchallenged mouse livers, CCL2/CCR2 blockade attenuated tumor growth, altered TAM phenotype and restored CD8+ T cell activity. This evidence concerns the gene CD8A and neoplasm.